For healthcare professionals facing the complexity of daily requirements in emergency situations, a new point-of-care test, Samsung IB B•R•A•H•M•S PCT assay, offers an integrated solution for accurate sepsis diagnosis and antibiotic stewardship.
The test, which recently received a CE mark for use in Europe, may further improve medical decision-making about risk assessment and therapy management. B-R-A-H-M-S PCT (procalcitonin) assays are known to clinicians for high-quality and reliable early detection of bacterial infections based on standardized cutoffs.
"With the addition of this new test, we will significantly improve our ability to make PCT testing available to a broader patient population in Europe, particularly for point-of-care diagnostics," said Marc Tremblay, president of Thermo Fisher’s clinical diagnostics business.
"Early diagnosis is key in preventing sepsis, a global problem resulting in greater mortality rates than prostate cancer, breast cancer and AIDS combined1. Early identification and treatment of sepsis reduces the cost of providing healthcare. Delayed sepsis treatment may involve an extended stay in the intensive care unit or complex antibiotic therapies."
As the first co-developed product by Thermo Fisher and Samsung Electronics, the Samsung IB B-R-A-H-M-S PCT test enables fast and easy Procalcitonin determination in acute care settings as testing results in 20 minutes while providing outstanding portability and connectivity.
The quantitative point of care test aids early detection and diagnosis of clinically relevant bacterial infections to assess the degree of severity and to prognosticate the outcome of systemic bacterial infection, sepsis, severe sepsis, and septic shock.
The Samsung IB B-R-A-H-M-S PCT test is not available for sale in some countries, including the United States.
The unique alliance between Samsung Electronics and Thermo Fisher will continue to bring further innovations in the point-of-care testing market to fulfill customer needs and improve patient outcomes.